Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Rating of "Buy" by Analysts

Key Points

• Monopar Therapeutics Inc. has been rated an average of "Buy" by eleven research firms, with eight issuers marking it as a buy and two as a strong buy.
• Recent price targets for Monopar stock from analysts range from $85 to $115, indicating potential upside from its current trading price of around $81.57.
• Institutional investors are actively engaging with Monopar, with notable new stakes purchased by firms such as Goldman Sachs Group and Affinity Asset Advisors totaling over $3 million in new investments.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) has been given an average rating of "Buy" by the eleven research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $105.6667.

A number of research analysts recently issued reports on the stock. Jones Trading upgraded shares of Monopar Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Friday, October 10th. BTIG Research upped their price target on shares of Monopar Therapeutics from $87.00 to $104.00 and gave the stock a "buy" rating in a research report on Thursday, September 25th. HC Wainwright set a $105.00 price objective on shares of Monopar Therapeutics and gave the company a "buy" rating in a report on Monday, September 29th. Oppenheimer set a $115.00 price target on shares of Monopar Therapeutics and gave the company an "outperform" rating in a research note on Thursday, October 2nd. Finally, Chardan Capital upped their price objective on shares of Monopar Therapeutics from $60.00 to $85.00 and gave the stock a "buy" rating in a research report on Thursday, September 25th.

Insiders Place Their Bets

In other news, major shareholder Tactic Pharma Llc sold 550,229 shares of the firm's stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $63.61, for a total transaction of $35,000,066.69. Following the completion of the sale, the insider owned 272,026 shares of the company's stock, valued at $17,303,573.86. This trade represents a 66.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 20.50% of the company's stock.

Hedge Funds Weigh In On Monopar Therapeutics

Several large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. bought a new stake in shares of Monopar Therapeutics during the 1st quarter worth $673,000. AlphaQuest LLC purchased a new position in shares of Monopar Therapeutics during the first quarter worth about $44,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Monopar Therapeutics during the first quarter worth about $328,000. Affinity Asset Advisors LLC bought a new stake in Monopar Therapeutics in the 1st quarter worth approximately $2,257,000. Finally, Jane Street Group LLC bought a new stake in Monopar Therapeutics in the 1st quarter worth approximately $377,000. 1.83% of the stock is currently owned by institutional investors.

Monopar Therapeutics Trading Up 0.3%

MNPR stock opened at $81.57 on Friday. Monopar Therapeutics has a 52 week low of $12.55 and a 52 week high of $105.00. The firm's 50-day moving average is $63.67 and its two-hundred day moving average is $46.83. The company has a market capitalization of $503.29 million, a price-to-earnings ratio of -24.50 and a beta of 1.42.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.12. On average, equities research analysts predict that Monopar Therapeutics will post -1.65 earnings per share for the current year.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.